Adjuvant Immunotherapy Breakthroughs in Lung Cancer from ESMO 2021

Now Viewing

EP: 1.Adjuvant Immunotherapy Breakthroughs in Lung Cancer from ESMO 2021

EP: 2.Neoadjuvant and Stage IV Immunotherapy Data Shaking Up Lung Cancer Paradigm

EP: 3.Living In a Targeted Therapy Revolution of NSCLC

EP: 4.It’s Not a Small World for Small Cell Lung Cancer Treatment

Good evening and welcome! Thank you for joining OncLive’s fourth episode of Thoracic Night Live, a program devoted to spotlighting the biggest topics in lung cancer and pivotal studies discussed at medical meetings throughout the year.

Live from New York City, I’m Dr Isabel Preeshagul, a medical oncologist at Memorial Sloan Kettering Cancer Center, and it’s great to be back on this program, this time as your host!

But tonight, it’s not just me. Virtually joining me is Dr Catherine Shu, an assistant professor of medicine and clinical director of the Thoracic Medical Oncology Service at Columbia University Herbert Irving Comprehensive Cancer Center, as well as Dr Ashish Saxena, an assistant professor of medicine at Weill Cornell Medical College and an assistant attending physician at the NewYork-Presbyterian Hospital.

Welcome both of you, and it’s an honor to share this virtual stage with you!

Tonight’s discussion is going to focus on some of the incredible findings that have read out in lung cancer from some recent medical meetings, including the 2021 World Conference on Lung Cancer and ESMO Congress. We’ll dig into some of the data as they relate to immunotherapy, targeted therapies, and even some exciting novel compounds across lung cancer subtypes.

Let’s kick this show off!